2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2398

Pauci-Immune Glomerulonephritis in the Elderly: Disease Severity and Outcomes
Abstract Number: 2325

PD-1 Signaling Promotes Suppressive Function of CD4⁺ Regulatory T Cells in (New Zealand Black x New Zealand White )F₁ Lupus-Prone Mice in a Dose-Dependent Manner
Abstract Number: 331

PDL241, a Novel Humanized Monoclonal Antibody, Reveals CD319 As a Therapeutic Target for Rheumatoid Arthritis
Abstract Number: 189

Pedal Swelling As a Characteristic Phenotype of the New Category of Autoinflammatory Disease Associated with NOD2 Gene Mutations
Abstract Number: 280

Pediatric Automated Neuropsychological Assessment Metrics As a Screening Tool for Neuropsychiatric Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 315

Pediatric Lupus Nephritis: Micrornas – Macro Inflammation
Abstract Number: 275

Pediatric Rheumatology Practitioners Experience with Biologics in Juvenile Dermatomyositis: Survey Results
Abstract Number: 2012

Pediatric Rheumatology Productivity: Results of the American Academy of Pediatrics 2010 Workforce Survey
Abstract Number: 2148

Peer to Peer Mentoring for Individuals with Early Inflammatory Arthritis: Feasibility Pilot
Abstract Number: 1657

Peg-IFNa/Ribavirin/Protease Inhibitor Combination Is Highly Effective in HCV-Mixed Cryoglobulinemia Vasculitis
Abstract Number: 160

Pegloticase Long-Term Safety: Data From the Open-Label Extension Trial
Abstract Number: 1153

Perceived Health-Related Quality of Life and Its Determining Factors in Children with Recent-Onset JIA
Abstract Number: 2407

Perceptions of the Chronic Disease Self-Management Program Among Low Income African American Women with Lupus
Abstract Number: 2423

Perceptions Regarding Cardiovascular Risk Factors and Barriers to Risk Reduction Among African American Women with Lupus
Abstract Number: 441

Performance of Anti-Cyclic Citrullinated Peptide Assays Differs in Healthy Subjects At Elevated Risk for Future Rheumatoid Arthritis and Subjects with Established Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].